The Critical Importance of Urine Sediment Examination

Examination technique matters: - Centrifuged, fresh sediment examined under 40× objective (not dipstick alone) - Low-power field (LPF): RBCs, WBCs, bacteria, casts - High-power field (HPF): crystals, bacteria detail - Always correlate with microscopy findings; dipstick findings without sediment confirmation are misleading

AIN: Red Flags

The classic triad of rash, fever, eosinophilia is present in only 10% of drug-induced AIN. More commonly, presentation is insidious:

Drug timeline is critical: - Beta-lactam antibiotics (nafcillin, oxacillin): 1–3 weeks exposure before AKI onset - Sulfonamides, NSAIDs, fluoroquinolones: Similar 1–3 week window - PPIs (proton pump inhibitors): Delayed, insidious onset; median 2–3 months of exposure; acute presentation rare (see [[ppi_kidney_report]]) - Checkpoint inhibitors: Variable, can occur weeks to months after initiation

GN: Red Flags

Active glomerulonephritis announces itself with an active urinary sediment:

2.1 History and Drug Timeline

The timing of drug exposure is diagnostic. A systematic medication history is essential:

Timeline Template:
─────────────────────────────────────────
[Start Drug A] ──── 10 days ──── [AKI Detected] ✓ Beta-lactam
[Start Drug B] ──── 3 months ──── [AKI Detected] ✓ PPI
[Start Drug C] ──── 1 week ──── [AKI Detected] ✓ NSAID

Gather: - Exact start date of each new medication - Any medication changes in the 3 months prior to AKI - Over-the-counter NSAIDs, herbal supplements (often forgotten) - Recent vaccinations (checkpoint inhibitors, rarely triggering AIN)

2.2 Urinalysis Pattern in AIN

Expected findings (in order of diagnostic weight):

1. Sterile pyuria (WBC >5 per HPF in absence of bacteria)
   • Present in 80–90% of drug-induced AIN
   • Must confirm absence of bacteria (urine culture negative)
   • Pyuria + positive culture = UTI, not AIN
2. WBC casts
   • Hallmark finding; correlates with interstitial lymphocyte/eosinophil infiltration
   • When present with sterile pyuria, specificity approaches 90%
   • May see hyaline casts and fine granular casts
3. Eosinophiluria (Hansel stain)
   • Hansel stain (methylene blue + safranin) > Wright-Giemsa
   • Specific (85%) but insensitive (30–60%)
   • If positive, strongly supports AIN; if negative, does NOT exclude it
   • Not routinely available; must request specifically
4. Mild proteinuria
   • Typically <1 g/day (often 0.5–1 g)
   • Helps distinguish from nephrotic GN
   • Dipstick may show 1+ or 2+ protein
5. RBCs
   • Non-specific; present in variable amounts
   • If dysmorphic or in casts, suspect concurrent GN

2.3 Urine Biomarkers: B2-Microglobulin and Tubular Markers

See detailed review at [[B2M_AIN_Comprehensive_Review]].

B2-microglobulin (B2M): - Normal filtered load is reabsorbed by proximal tubule - Elevated urine B2M indicates proximal tubular dysfunction - In AIN, tubular infiltration and edema cause tubular leak - Sensitivity 70–80%, specificity 70–80% for AIN diagnosis when combined with clinical context - Not specific (also elevated in tubular diseases, early CKD)

KIM-1 (Kidney Injury Molecule-1), NAG (N-acetyl-β-glucosaminidase): - Research biomarkers for tubular injury - Not yet standard clinical practice

2.4 Historical: Gallium-67 Scan

Gallium-67 imaging was used to demonstrate interstitial accumulation; now largely replaced by kidney biopsy for diagnostic certainty. Rarely ordered in current practice.

2.5 PPI-Associated AIN: A Special Case

See detailed review at [[ppi_kidney_report]].

Distinguishing features of PPI-associated AIN:

2.6 When to Perform Kidney Biopsy in Suspected AIN

Indications for biopsy: 1. Diagnostic uncertainty: Active sediment present but serologies are negative and diagnosis remains unclear 2. No improvement after drug withdrawal: If creatinine plateaus or worsens after stopping the presumed offending agent 3. Consideration of corticosteroid therapy: Some nephrologists biopsy to confirm AIN before giving high-dose steroids, especially if steroid risks are high 4. Fever/rash/eosinophilia triad present: Biopsy confirms diagnosis; guides prognosis

Contraindications (relative): - Solitary kidney (increased bleed risk; small needle biopsy possible) - Uncontrolled hypertension (HTN >180/110 mmHg increases bleed risk) - Active bleeding diathesis or anticoagulation that cannot be reversed - Infection at biopsy site

Timing: - Biopsy in first 2 weeks after AKI onset is ideal (fresh infiltrate) - Delayed biopsy (>4 weeks) may show fibrosis and chronic changes instead of acute infiltrate

2.7 Kidney Biopsy Findings: Light Microscopy and Immunofluorescence

Light microscopy: - Interstitial inflammation: Predominantly lymphocytes (T cells), occasional plasma cells and eosinophils - Tubulitis: Infiltrating cells within tubular epithelium; tubular basement membrane (TBM) intact - Interstitial edema: Acute swelling; no prominent fibrosis - Glomeruli: Typically normal or minimal changes (unless concurrent GN)

Immunofluorescence (IF): - Usually negative or minimal staining (this distinguishes AIN from immune GN) - Occasional IgM, C3 in tubular basement membrane (non-specific) - If linear IgG or strong granular IgA/IgG → suspect concurrent anti-GBM disease or IgA nephropathy

Electron microscopy (EM): - Not routinely needed - Shows podocyte effacement if concurrent FSGS or nephrotic component

2.8 AIN Treatment and Prognosis

Immediate management: 1. Discontinue offending drug (highest priority) 2. Assess recovery: Follow creatinine daily for 5–7 days

If creatinine not improving after 5–7 days of drug cessation: - Consider kidney biopsy (if diagnosis uncertain) - Consider corticosteroids: - Methylprednisolone 500 mg IV daily × 3 days, then oral prednisone 1 mg/kg (max 80 mg) daily × 3–4 weeks, then taper - Or: Oral prednisone 1 mg/kg/day × 4 weeks then taper - Evidence is mixed; benefit clearer if given within 2 weeks of onset and if eosinophilia/WBC casts present

Prognosis: - Full recovery of GFR: 50–60% of patients - Partial recovery: 25–35% (residual CKD) - No recovery requiring dialysis: 5–10% - Worse prognosis: delayed presentation (>3 weeks), advanced age, baseline CKD, need for dialysis at presentation

See detailed clinical guidance at [[acute-interstitial-nephritis-review]].

3.1 Serologic Workup Panel

The complete GN serologic panel includes:

Panel:
├── c-ANCA (cytoplasmic) + PR3-ANCA
│   └── Granulomatosis with polyangiitis (GPA, formerly Wegener's)
│
├── p-ANCA (perinuclear) + MPO-ANCA
│   └── Microscopic polyangiitis (MPA)
│       Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss)
│
└── Negative ANCA
    └── Rules out pauci-immune ANCA vasculitis

3.2 Complement Pattern Table: Differential Diagnosis at a Glance

This table is essential for rapid diagnostic reasoning:

3.3 RPGN: The Emergency Diagnosis

RPGN = Rapidly Progressive Glomerulonephritis

Definition: GN with crescents involving ≥50% of glomeruli on light microscopy.

Clinical hallmarks: - Rapid rise in creatinine: Days to weeks - Active urinary sediment: RBC casts, dysmorphic RBCs, proteinuria - Systemic symptoms variable: May be absent (pauci-immune) or prominent (granulomatosis with polyangiitis)

Three pathologic categories (define therapy):

Critical point: > [!warning] > RPGN is a nephrology emergency. Once crescentic GN is suspected (RBC casts + rapidly rising creatinine + active urine sediment), start empiric treatment BEFORE biopsy returns. Delay of even days can result in irreversible loss of renal function requiring long-term dialysis.

Empiric treatment initiated while awaiting biopsy: - Pulse methylprednisolone: 500 mg IV daily × 3 days - Cyclophosphamide or rituximab: Load dose (RTX preferred in current practice) - Consider plasmapheresis if pulmonary hemorrhage or severe oliguric AKI

4.1 The Positive ANA in Infective Endocarditis

See [[Lupus vs IE|Lupus vs IE Case Report]].

Clinical scenario:

Patient: 68-year-old male with fever, murmur, hematuria, ANA 1:1280
Initial impression: "Lupus nephritis—start immunosuppression"
Result if wrong: Worsening infection, abscess, embolic complications

Key differentiators between IE and lupus:

Clinical lesson: - Always obtain blood cultures before antibiotics in fever + AKI - In IE, ANA can be positive due to polyclonal B-cell activation and circulating immune complexes - Anti-dsDNA is specific for lupus; if positive, supports lupus; if negative with high ANA, think IE - Echocardiography (TEE preferred) is diagnostic for IE; rules out lupus mimicry

4.2 Lupus Nephritis: Renal-First Presentation and Serologically Quiet Disease

See [[Lupus_Nephritis_Renal_First_Serologically_Quiet_Case_Report]].

Clinical scenario:

Patient: 28-year-old female with AKI, RBC casts, proteinuria
Labs: ANA 1:160 (borderline), dsDNA negative, C3 low, C4 normal
Initial assessment: "Not lupus (negative dsDNA)"
Biopsy result: Lupus nephritis, Class IV-S (diffuse proliferative)

Serologically quiet lupus nephritis: - Occurs in 5–10% of lupus patients with renal involvement - ANA may be negative or low-titer at presentation - dsDNA may be negative initially; converts to positive within weeks to months - Diagnosis is by kidney biopsy showing full house IF pattern

IF pattern in lupus: - Full house: IgG, IgA, IgM, C3, C1q all positive (pathognomonic) - C1q positivity correlates with proliferative forms and disease activity - Tubular basement membrane staining often prominent

Management approach: - Biopsy strongly considered if: - Active urinary sediment (RBC casts, dysmorphic RBCs) + renal dysfunction - Low complement levels (C3, C4 low) - Any positive autoantibody (even if dsDNA negative) - Biopsy needed to: - Confirm lupus nephritis - Classify (WHO Class I–VI) to guide therapy intensity - Assess chronicity (fibrosis, tubular atrophy) to estimate prognosis

5.1 Indications for Kidney Biopsy in AKI

Diagnostic indications:

1. Active sediment with negative serology: RBC casts present, serologic workup negative (no ANCA, no anti-GBM, no lupus serology) — biopsy identifies etiology
2. Serologically quiet disease: Suspected lupus or other immune GN with atypical serology
3. Uncertain ATN vs. AIN vs. GN: Clinical presentation ambiguous; biopsy clarifies
4. Suspected drug-induced: Biopsy confirms AIN before corticosteroids given
5. RPGN: Rapid decline with crescents likely; biopsy categorizes (anti-GBM vs. immune complex vs. pauci-immune) to guide specific therapy

Prognostic indications:

6. Assess chronicity: Fibrosis score, tubular atrophy severity predict recovery potential and guide steroid use
7. Baseline before treatment: Certain MPGN or GPA cases benefit from biopsy to assess baseline inflammation vs. chronic changes

5.2 Contraindications to Kidney Biopsy

5.3 Biopsy Technique and Yield

Standard percutaneous needle biopsy: - Ultrasound-guided or fluoroscopy-guided (ultrasound preferred; real-time visualization) - 18-gauge needle (standard); 20-gauge if bleeding risk - Obtain 2–3 core samples minimum: 8–10 mm length optimal - Light microscopy, immunofluorescence, and electron microscopy from same tissue samples

Success rate: 95–98% diagnostic adequacy with experienced operator

Post-biopsy hemorrhage risk: 0.5–1% clinically significant bleeding; <0.1% need intervention/transfusion

5.4 Pathologic Interpretation: What Each Modality Reveals

6.1 Flowchart: AKI with Active Sediment

AKI Diagnosis
    ↓
Urinalysis with microscopy
    ↓
─────────────────────────────────────
│
├─ INACTIVE sediment (no casts, no hematuria)
│   └─→ ATN vs. Prerenal
│       → FeNa, BUN:Cr, trial of fluids
│
└─ ACTIVE sediment (casts, hematuria, pyuria, WBC casts)
    ↓
    ├─ RBC CASTS or dysmorphic RBCs?
    │  ├─ YES → GN likely
    │  │   └─→ [See GN algorithm below]
    │  │
    │  └─ NO, but WBC casts + sterile pyuria?
    │     ├─ YES → AIN likely
    │     │   └─→ [See AIN algorithm below]
    │     │
    │     └─ NO → Mixed or uncertain
    │         └─→ [Obtain serologies + consider biopsy]

6.2 AIN Diagnostic Algorithm

Suspected AIN (pyuria + WBC casts)
    ↓
Step 1: Drug Timeline Review
├─ Drug exposure 1–3 weeks before AKI?
│  └─ Beta-lactam, sulfonamide, NSAID, FQ → LIKELY
├─ PPI use for any duration?
│  └─ Any duration → POSSIBLE (delayed presentation)
├─ Other drugs (statins, diuretics, allopurinol)?
│  └─ Consider, but less common
    ↓
Step 2: Clinical Features
├─ Rash, fever, eosinophilia?
│  └─ If present (10% of cases) → Supportive
├─ Mucosal ulcers, arthralgias?
│  └─ → Supportive
    ↓
Step 3: Laboratory Testing
├─ Urine eosinophils (Hansel stain)?
│  └─ If positive → Highly specific
├─ Proteinuria?
│  └─ <1 g/day expected
├─ Eosinophilia (blood)?
│  └─ Present in ~30% (not sensitive)
    ↓
Step 4: Decision Tree

  ┌─────────────────────────────────────────────────┐
  │ Is diagnosis certain (classic history + features)? │
  └─────────────────────────────────────────────────┘
       ↙ YES              ↘ NO / UNCERTAIN
       │                   │
       ↓                   ↓
    STOP offending    Consider BIOPSY if:
    drug               • Diagnosis uncertain
       │               • No improvement after drug stop (5–7 days)
       ↓               • Considering corticosteroids
    Monitor Cr daily
       │
       ├─ Cr improves → Observe, support renal function
       │
       └─ Cr plateaus/worsens → BIOPSY + Consider steroids
              ↓
           [See Treatment]

6.3 GN Diagnostic Algorithm

Suspected GN (RBC casts / dysmorphic RBCs)
    ↓
URGENT: Obtain comprehensive serology STAT
    ├─ C3, C4 (complement)
    ├─ ANCA (c-ANCA + p-ANCA, with PR3/MPO reflex)
    ├─ Anti-GBM
    ├─ ANA, anti-dsDNA
    ├─ Hepatitis B/C, HIV
    ├─ ASO titer, anti-DNase B (if post-infectious suspected)
    ├─ Cryoglobulins (if vasculitis suspected)
    ├─ SPEP/UPEP/FLC (if monoclonal disease suspected)
    └─ Blood cultures (if endocarditis suspected)
    ↓
    ├─ RPGN features? (Creatinine rising >0.3 mg/dL/day, oliguria, hemoptysis)
    │  └─ YES → START EMPIRIC THERAPY immediately
    │       ├─ Methylprednisolone 500 mg IV × 3 days
    │       ├─ Cyclophosphamide or Rituximab
    │       └─ Consider plasmapheresis
    │       └─→ Continue therapy while awaiting biopsy
    │
    └─ Non-RPGN features? (Stable renal function, non-oliguric)
       └─ YES → Await serologic results (24–48 hours)
    ↓
    ┌──────────────────────────────────────────────────┐
    │ Interpret Complement Pattern + Serology           │
    └──────────────────────────────────────────────────┘
    │
    ├─ c-ANCA/PR3 + normal complement → GPA
    │  └─→ Biopsy shows: ANCA vasculitis, crescents, pauci-immune IF
    │  └─→ Treatment: RTX or CYC + corticosteroids
    │
    ├─ p-ANCA/MPO + normal complement → MPA
    │  └─→ Biopsy shows: Pauci-immune crescentic GN
    │  └─→ Treatment: RTX or CYC + corticosteroids
    │
    ├─ Anti-GBM (+) → Goodpasture syndrome
    │  └─→ Biopsy shows: Linear IgG along GBM, crescents
    │  └─→ Treatment: Plasmapheresis + CYC + corticosteroids
    │  └─→ Urgent treatment; prognosis poor if dialysis-dependent
    │
    ├─ ANA (+), anti-dsDNA (+), C3 & C4 LOW → Lupus nephritis
    │  └─→ Biopsy shows: Full house IF, class I–VI
    │  └─→ Treatment: Class-dependent; MMF or CYC + steroids typical
    │
    ├─ ANA low/borderline, C3/C4 normal/low, dsDNA (–) → Serologically quiet or other GN
    │  └─→ BIOPSY needed for diagnosis
    │  └─→ Possible diagnoses:
    │       ├─ Lupus nephritis (renal-first)
    │       ├─ IgA nephropathy
    │       ├─ Post-infectious GN
    │       └─ Other MPGN
    │
    ├─ Low C3 (normal C4), no ANCA/anti-GBM/ANA → Post-infectious GN likely
    │  └─→ History: Recent strep infection, IVDU, endocarditis risk
    │  └─→ ASO/anti-DNase B positive
    │  └─→ Treatment: Supportive; most resolve spontaneously
    │
    ├─ Cryoglobulins (+), HCV (+), low C4 → Cryoglobulinemia
    │  └─→ Biopsy shows: MPGN pattern, cryoglobulin deposits
    │  └─→ Treatment: Antiviral (DAA), corticosteroids, RTX if severe
    │
    └─ SPEP/UPEP monoclonal spike, FLC elevated → Paraprotein-related GN
       └─→ Biopsy shows: LC-dominant deposition, membranoproliferative pattern
       └─→ Treatment: Hematology referral, chemotherapy or proteasome inhibitor
    ↓
PERFORM KIDNEY BIOPSY if:
├─ Diagnosis remains uncertain after serologies
├─ Serology negative but sediment active
├─ Need to classify GN severity (for treatment intensity)
├─ Assessing chronicity/prognosis
└─ RPGN with atypical features
    ↓
    Based on biopsy categorization:
    ├─ IF category (anti-GBM vs. immune complex vs. pauci-immune)
    ├─ LM chronicity score
    └─ → Refine therapy and prognosis